Bangzhi Zhang

Prof. Dr. Bangzhi Zhang


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
DWDan Wang
Dan Wang
ZYZhibin Yan
Zhibin Yan
LBLili Bu
Lili Bu
CAChunmei An
Chunmei An
BDBochuan Deng
Bochuan Deng
JXJunqiu Xie
Junqiu Xie

15 October 2014 in Journal of Peptide Science
Verified
Journal Article
Closed access
PDF file
YWYang Wang
Yang Wang
JCJianbo Chen
Jianbo Chen
XZXin Zheng
Xin Zheng
XYXiaoli Yang
Xiaoli Yang
PMPanpan Ma
Panpan Ma
YCYuan Chen
Yuan Chen

1 November 2020 in Life Sciences
Verified
Journal Article
Closed access
BDBochuan Deng
Bochuan Deng
WYWenle Yang
Wenle Yang
DWDan Wang
Dan Wang
LCLu Cheng
Lu Cheng
LBLili Bu
Lili Bu
BZBangzhi Zhang
Bangzhi Zhang

1 May 2018 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
MZMingyan Zhang
Mingyan Zhang
ZYZhibin Yan
Zhibin Yan
LBLili Bu
Lili Bu
CAChunmei An
Chunmei An
DWDan Wang
Dan Wang
BZBangzhi Zhang
Bangzhi Zhang
Rapeseed protein-derived antioxidant peptide RAP alleviates renal fibrosis through MAPK/NF-kappaB signaling pathways in diabetic nephropathy Mingyan Zhang,1,* Zhibin Yan,1,* Lili Bu,1 Chunmei An,2 Dan Wang,1 Xin Liu,1 Jianfeng Zhang,1 Wenle Yang,2 Bochuan Deng,1 Junqiu Xie,2 Bangzhi Zhang1,2 1Institute of Biochemistry and Molecular Biology, School of Life Sciences, Lanzhou University, Lanzhou, China; 2Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China *These authors contributed equally to this work Introduction: Kidney fibrosis is the main pathologic change in diabetic nephropathy (DN), which is the major cause of end-stage renal disease. Current therapeutic strategies slow down but cannot reverse the progression of renal dysfunction in DN. Plant-derived bioactive peptides in foodstuffs are widely used in many fields because of their potential pharmaceutical and nutraceutical benefits. However, this type of peptide has not yet been studied in renal fibrosis of DN. Previous studies have indicated that the peptide YWDHNNPQIR (named RAP), a natural peptide derived from rapeseed protein, has an antioxidative stress effect. The oxidative stress is believed to be associated with DN. The aim of this study was to evaluate the pharmacologic effects of RAP against renal fibrosis of DN and high glucose (HG)-induced mesangial dysfunction. Materials and methods: Diabetes was induced by streptozotocin and high-fat diet in C57BL/6 mice and these mice were treated by subcutaneous injection of different doses of RAP (0.1 mg/kg and 0.5 mg/kg, every other day) or PBS for 12 weeks. Later, functional and histopathologic analyses were performed. Parallel experiments verifying the molecular mechanism by which RAP alleviates DN were carried out in HG-induced mesangial cells (MCs). Results: RAP improved the renal function indices, including 24-h albuminuria, triglyceride, serum creatinine, and blood urea nitrogen levels, but did not lower blood glucose levels in DN mice. RAP also simultaneously attenuated extracellular matrix accumulation in DN mice and HG-induced MCs. Furthermore, RAP reduced HG-induced cell proliferation, but it showed no toxicity in MCs. Additionally, RAP inhibited the mitogen-activated protein kinase (MAPK) and nuclear factor κB (NF-κB) signaling pathways. Conclusion: RAP can attenuate fibrosis in vivo and in vitro by antagonizing the MAPK and NF-κB pathways. Keywords: antioxidant peptide, RAP, diabetic nephropathy, extracellular matrix, kidney fibrosis, MAPK, NF-κB

19 May 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
XGXiaomin Guo
Xiaomin Guo
TYTiantian Yan
Tiantian Yan
JRJing Rao
Jing Rao
XYXin Yue
Xin Yue
XPXiong Pei
Xiong Pei
JXJunqiu Xie
Junqiu Xie
The dramatic increase in antimicrobial resistance (AMR) highlights an urgent need to develop new antimicrobial therapies. Thus, antimicrobial peptides (AMPs) have emerged as promising novel antibiotic alternatives. Feleucin-K3 is an amphiphilic α-helical nonapeptide that has powerful antimicrobial activity. In our previous study, it was found that the fourth residue of Feleucin-K3 is important for antimicrobial activity. After α-(4-pentenyl)-Ala was introduced into this position, both the antimicrobial activity and stability were greatly improved. Herein, to improve the limitations of Feleucin-K3, this unnatural amino acid was further introduced into different positions of Feleucin-K3. Among these synthetic Feleucin-K3 analogs, the N-terminal-substituted analog Feleucin-K65 (K65) and C-terminal-substituted analog Feleucin-K70 (K70) had preferable antimicrobial activity. In particular, their antimicrobial activities against multidrug-resistant bacteria were more potent than that of antibiotics. The stabilities of these peptides in salt and serum environments were improved compared with those of Feleucin-K3. In addition, these analogs had low hemolytic activity and AMR. More importantly, they effectively inhibited biofilm formation and exhibited considerable efficacy compared with traditional antibiotics against biofilm infection caused by methicillin-resistant Staphylococcus aureus (MRSA). In antimicrobial mechanism studies, K65 and K70 mainly permeated the outer membrane and depolarized the cytoplasmic membrane, resulting in cellular component leakage and cell death. In summary, analogs K65 and K70 are potential antimicrobial alternatives to solve the antibiotic crisis.

16 February 2025 in Biochemical Pharmacology
Verified
Journal Article
Closed access
SWShuping Wang
Shuping Wang
JHJingling Huang
Jingling Huang
TZTingyu Zeng
Tingyu Zeng
YCYali Chen
Yali Chen
JDJi Dezhong
Ji Dezhong
BZBangzhi Zhang
Bangzhi Zhang